The genetic basis of mast cell activation disease - looking through a glass darkly

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 2, 2015, Pages 75-89

  Molderings, Gerhard J ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Germline mutations; Inheritance; Mast cell activation disease; Mast cell activation syndrome; Mast cell leukemia; Somatic mutations; Systemic mastocytosis

Indexed keywords

CBL PROTEIN; CRYOPYRIN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR;

ASLX1 GENE; CBL GENE; DNA METHYLATION; DNMT3A GENE; ETV6 GENE; EZH2 GENE; GENE; GENE IDENTIFICATION; GERMLINE MUTATION; HUMAN; HUMAN GENOME; IDH2 GENE; IDIOPATHIC DISEASE; IDIOPATHIC SYSTEMIC MAST CELL ACTIVATION SYNDROME; KIT GENE; MAST CELL LEUKEMIA; NLRP3 GENE; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; RASGRP4 GENE; REVIEW; RUNX1 GENE; SETBP1 GENE; SF3B1 GENE; SOMATIC MUTATION; SRSF2 GENE; SYSTEMIC MASTOCYTOSIS; TET2 GENE; U2AF1 GENE; ADAPTIVE IMMUNITY; CELL CLONE; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; LEUKEMIA, MAST-CELL; MAST CELL; MASTOCYTOSIS, CUTANEOUS; MASTOCYTOSIS, SYSTEMIC; MUTATION; PATHOLOGY; RNA SPLICING; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; CLONE CELLS; EPIGENESIS, GENETIC; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; LEUKEMIA, MAST-CELL; MAST CELLS; MASTOCYTOSIS, CUTANEOUS; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RNA SPLICING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84927174961     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.09.001     Document Type: Review

References (149)

1. Poglio S., De Toni-Costes F., Arnaud E., Laharrague P., Espinosa E., Casteilla L., et al. Adipose tissue as a dedicated reservoir of functional mast cell progenitors. Stem Cells 2010, 28:2065-2072.
2. Gri G., Frossi B., D'Inca F., Danelli L., Betto E., Mion F., et al. Mast cell: an emerging partner in immune interaction. Front Immunol 2012, 3:120.
3. Molderings G.J., Brettner S., Homann J., Afrin L.B. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 2011, 4:10.
4. Afrin L.B. Polycythemia from mast cell activation syndrome: lessons learned. Am J Med Sci 2011, 342:44-49.
5. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215-225.
6. Afrin L.B., Molderings G.J. A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol 2014, 3:1-17.
7. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
8. Valent P., Akin C., Escribano L., Fodinger M., Hartmann K., Brockow K., Castells M., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
9. Molderings G.J., Kolck U.W., Scheurlen C., Brüss M., Homann J., Von Kügelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 2007, 42:1045-1053.
10. Molderings G.J., Meis K., Kolck U.W., Homann J., Frieling T. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010, 62:721-727.
11. Hamilton M.J., Hornick J.L., Akin C., Castells M.C., Greenberger N.J. Mast cell activation syndrome: Anewly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011, 128:147-152.
12. Pardanani A., Chen D., Abdelrahman R.A., Reichard K.K., Zblewski D., Wood A.J., et al. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013, 27:2091-2094.
13. Valent P., Sotlar K., Sperr W.R., Escribano L., Yavuz S., Reiter A., et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014, 25:1691-1700.
14. Hermine O., Lortholary O., Leventhal P.S., Catteau A., Soppelsa F., Baude C., et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS ONE. 2008, 3:e2266.
15. Lanternier F., Cohen-Akenine A., Palmerini F., Feger F., Yang Y., Zermati Y., et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 2008, 3:e1906.
16. Escribano L., Alvarez-Twose I., Sánchez-Muñoz L., Garcia-Montero A., Núñez R., Almeida J., et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009, 124:514-521.
17. Alvarez-Twose I., González de Olano D., Sánchez-Muñoz L., Matito A., Esteban-López M.I., Vega A., et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010, 125:1269-1278.
18. Merante S, Magliacane D, Neri I, Pascutto C, Zanotti R, Forer I, et al. The New Italian Mastocytosis Registry. 53rd ASH Annual Meeting and Exposition 2010, Poster 3805, http://ash.confex.com/ash/2010/webprogram/Paper28567.html.
19. Haenisch B., Nöthen M.M., Molderings G.J. Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology 2012, 137:197-205.
20. van Doormaal J.J., Arends S., Brunekreeft K.L., van der Wal V.B., Sietsma J., van Voorst Vader P.C., et al. Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol 2013, 131:1429-1431.
21. Cohen S.S., Skovbo S., Vestergaard H., Kristensen T., Møller M., Bindslev-Jensen C., et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 2014, 166:521-528.
22. Lim K.H., Tefferi A., Lasho T.L., Finke C., Patnaik M., Butterfield J.H., et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736.
23. Molderings G.J., Haenisch B., Bogdanow M., Fimmers R., Nöthen M.M. Familial occurrence of systemic mast cell activation disease. PLoS One 2013, 8:e76241.
24. Lucas H.J., Brauch C.M., Settas L., Theoharides T.C. Fibromyalgia--new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006, 19:5-10.
25. Blanco I., Béritze N., Argüelles M., Cárcaba V., Fernández F., Janciauskiene S., et al. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010, 29:1403-1412.
26. Maeshima E., Furukawa K. A case of fibromyalgia syndrome with anaphylaxis induced by intradermal injection of purified protein derivative. Mod Rheumatol 2013, 23:593-596.
27. Santos J., Guilarte M., Alonso C., Malagelada J.R. Pathogenesis of issitable bowel syndrome: The mast cell connection. Scand J Gastroenterol 2005, 40:129-140.
28. Klooker T.K., Braak B., Koopman K.E., Welting O., Wouters M.M., van der Heide S., et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010, 59:1213-1221.
29. Frieling T., Meis K., Kolck U.W., Homann J., Hülsdonk A., Haars U., et al. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol 2011, 49:191-194.
30. Frieling T., Schemann M., Pehl C. Irritable bowel syndrom--a misnomer?. Z Gastroenterol 2011, 49:577-578.
31. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c- kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci 1995, 92:10560-10564.
32. Longley B.J., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.Z., et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci 1999, 96:1609-1614.
33. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
34. Lundberg P., Karow A., Nienhold R., Looser R., Hao-Shen H., Nissen I., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014, 123:2220-2228.
35. Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta haematol 2005, 114:61-69.
36. Bodemer C., Hermine O., Palmérini F., Yang Y., Grandpeix-Guyodo C., Leventhal P.S., et al. Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
37. Orfao A., Garcia-Montero A.C., Sanchez L., Escribano L. REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007, 138:12-30.
38. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Sanchez M.L., Nunez R., Prados A., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
39. Kristensen T., Broesby-Olsen S., Vestergaard H., Bindslev-Jensen C., Møller M.B. on behalf of the Mastocytosis Centre Odense University Hospital (MastOUH). Circulating KIT D816V mutation positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012, 89:42-46.
40. Teodosio C., García-Montero A.C., Jara-Acevedo M., Alvarez-Twose I., Sánchez-Muñoz L., Almeida J., et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012, 26:951-958.
41. Roskoski R. Structure and regulation of Kit protein-tyrosine kinase - The stem cell factor receptor. Bichem Biophys Res Commun 2005, 338:1307-1315.
42. Bougherara H., Subra F., Crépin R., Tauc P., Auclair C., Poul M.A. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 2009, 7:1525-1533.
43. Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010, 116:2429-2437.
44. Gilfillan A.M., Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009, 228:149-169.
45. Mayerhofer M., Gleixner K.V., Hoelbl A., Florian S., Hoermann G., Aichberger K.J., Bilban M., Esterbauer H., et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008, 180:5466-5476.
46. Teodosio C., García-Montero A.C., Jara-Acevedo M., Sánchez-Muñoz L., Alvarez-Twose I., Núñez R., et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010, 125:719-726.
47. Yang Y., Létard S., Borge L., Chaix A., Hanssens K., Lopez S., et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010, 116:1114-1123.
48. Broesby-Olsen S., Kristensen T., Vestergaard H., Brixen K., Møller M.B., Bindslev-Jensen C. Mastocytosis Centre Odense University Hospital (MastOUH). KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol 2013, 132:723-728.
49. Hassan H.T. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res 2009, 33:5-10.
50. Fritsche-Polanz R., Fritz M., Huber A., Sotlar K., Sperr W.R., Mannhalter C., et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 2010, 4:335-346.
51. Sotlar K., Colak S., Bache A., Berezowska S., Krokowski M., Bültmann B., Valent P., Horny H.P. Variable presence of KIT(D816V) in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010, 220:586-595.
52. McClintock-Treep S.A., Horny H.P., Sotlar K., Foucar M.K., Reichard K.K. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation. J Clin Pathol 2009, 62:1147-1149.
53. Gotlib J., Berubé C., Growney J.D., Chen C.C., George T.I., Williams C., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106:2865-2870.
54. Soucie E., Hanssens K., Mercher T., Georgin-Lavialle S., Damaj G., Livideanu C., et al. In aggressive forms of mastocytosis TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012, 120:4846-4849.
55. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
56. Rakheja D., Medeiros L.J., Bevan S., Chen W. The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms. Front Oncol 2013, 3:169.
57. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16:387-397.
58. Abdel-Wahab O., Adli M., LaFave L.M., Gao J., Hricik T., Shih A.H., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
59. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627.
60. Hanssens K., Brenet F., Agopian J., Georgin-Lavialle S., Damaj G., Cabaret L., et al. SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 2014, 99:830-835.
61. Chan E.C., Bai Y., Bandara G., Simakova O., Brittain E., Scott L., et al. KIT GNNK splice variants: Expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. Exp Hematol 2013, 41:870-881.
62. Trimarchi T., Ntziachristos P., Aifantis I. A new player SETs in myeloid malignancy. Nat Genet 2013, 45:846-847.
63. Damaj G., Joris M., Chandesris O., Hanssens K., Soucie E., Canioni D., et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014, 9:e85362.
64. Traina F., Visconte V., Jankowska A.M., Makishima H., O'Keefe C.L., Elson P., et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A. ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012, 7:e43090.
65. Schwaab J., Schnittger S., Sotlar K., Walz C., Fabarius A., Pfirrmann M., et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2014, 122:2460-2466.
66. Swolin B., Rödjer S., Roupe G. Cytogenetic studies in patients with mastocytosis. Cancer Genet Cytogenet 2000, 120:131-135.
67. Swolin B., Rödjer S., Ogärd I., Roupe G. Trisomies 8 and 9 not detected with fish in patients with mastocytosis. Am J Hematol 2002, 70:324-325.
68. Jost E., Michaux L., van den Abeele M., Boland B., Latinne D., Godfraind C., et al. Complex karyotype and absence of mutation in the c- kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia and brain damage. Ann Hematol 2001, 80:302-307.
69. Valent P., Akin C., Sperr W.R., Mayerhofer M., Födinger M., Fritsche-Polanz R., et al. Mastocytosis: Pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46:35-48.
70. Won D., Chi H.S., Shim H., Jang S., Park C.J., Lee J.H. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients. Leuk Res 2013, 37:883-888.
71. Wang S.A., Hutchinson L., Tang G., Chen S.S., Miron P.M., Huh Y.O., et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013, 88:219-224.
72. Georgin-Lavialle S., Lhermitte L., Dubreuil P., Chandesris M.O., Hermine O., Damaj G. Mast cell leukemia. Blood 2013, 121:1285-1295.
73. Ning Z.Q., Li J., Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001, 97:3559-3567.
74. Yang Y., Li L., Wong G.W., Krilis S.A., Madhusudhan M.S., Sali A., et al. RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function. J Biol Chem 2002, 277:25756-25774.
75. Gülen T., Sander B., Nilsson G., Palmblad J., Sotlar K., Horny H.P., et al. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. Med Oncol 2012, 29:3540-3546.
76. Bae M.H., Kim H.K., Park C.J., Seo E.J., Park S.H., Cho Y.U., et al. A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. Ann Lab Med 2013, 33:125-129.
77. Pardanani A., Lim K.H., Lasho T.L., Finke C.M., McClure R.F., Li C.Y., et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010, 115:150-151.
78. Cardet J.C., Castells M.C., Hamilton M.J. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep 2013, 13:10-18.
79. Verma D., Särndahl E., Andersson H., Eriksson P., Fredrikson M., Jönsson J.I., et al. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production. PLoS One 2012, 7:e34977.
80. Nakamura Y., Franchi L., Kambe N., Meng G., Strober W., Núñez G. Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity 2012, 37:85-95.
81. Haenisch B., Fröhlich H., Herms S., Molderings G.J. Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. Immunogenetics 2014, 66:287-297.
82. Kohno M., Yamasaki S., Tybolewicz V.L.J., Saito T. Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 2005, 105:2059-2065.
83. Aichberger K.J., Gleixner K.V., Mirkina I., Cerny-Reiterer S., Peter B., Ferenc V., et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009, 114:5342-5351.
84. Karlberg M., Ekoff M., Labi V., Strasser A., Huang D., Nilsson G. Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death Dis 2010, 1:e43.
85. Burks K.D., Wenzel S.E., Jones S.M. Familial cases of mast cell diseases [abstract]. J Invest Med 2005, 53:S300.
86. Zanotti R., Simioni L., Garcia-Montero A.C., Perbellini O., Bonadonna P., Caruso B., et al. Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. J Allergy Clin Immunol 2013, 131:605-607.
87. Torrelo A., Alvarez-Twose I., Escribano L. Childhood mastocytosis. Curr Opin Pediatr 2012, 24:480-486.
88. Tang X., Boxer M., Drummond A., Ogston P., Hodgins M., Burden A.D. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004, 41:e88.
89. Foster R., Byrnes E., Meldrum C., Griffith R., Ross G., Upjohn E., et al. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 2008, 159:1160-1169.
90. Wasag B., Niedoszytko M., Piskorz A., Lange M., Renke J., Jassem E., et al. Novel activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011, 39:859-865.
91. Georgin-Lavialle S., Le Saché-de Peufeilhoux L., Martin L., Soucie E., Bruneau J., Barete S., et al. Absence of circulating mast cell precursors in paediatric mastocytosis: could it reflect a different pathophysiology between adults and children with mastocytosis?. J Eur Acad Dermatol Venereol 2014, 28:967-971.
92. Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G., Capella C., et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001, 92:657-662.
93. Uzzaman A., Maric I., Noel P., Kettelhut B.V., Metcalfe D.D., Carter MC: Pediatric-onset mastocytosis. A long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer 2009, 53:629-634.
94. Lange M., Niedoszytko M., Renke J., Gleń J., Nedoszytko B. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol 2013, 27:97-102.
95. Noack F., Escribano L., Sotlar K., Nunez R., Schuetze K., Valent P., et al. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c- Kit mutation ASP- 816-VAL. Leuk Lymphoma 2003, 44:313-319.
96. Vogel N.M., Lichtin A.E., Hsieh F.H. Longitudinal disease progression in mastocytosis syndromes: a retrospective chart review. J Allergy Clin Immunol 2006, 117(Suppl):S125.
97. Bursztejn A.C., Bronner M., Kanny G., Barbaud A., Morisset M., Jonveaux P. Genetic evaluation of familial mastocytosis [abstract]. J Invest Dermatol 2009, 129:2528.
98. Bhamidimarri K., Sidhu L., Xie J., Pulakhandam U., Gumstae V. Gastrointestinal manifestations in cutaneous mastocytosis evolving into systemic mastocytosis. Am J Gastroenterol 2010, 105(Suppl 1):S348.
99. Rosbotham J.L., Malik N.M., Syrris P., Jeffery S., Bedlow A., Gharraie S., et al. Lack of c-kit mutation in familial urticaria pigmentosa. Br J Dermatol 1999, 140:849-852.
100. Offidani A., Cellini A., Simonetti O., Bossi G. Urticaria pigmentosa in monozygotic twins. Arch Dermatol 1994, 130:935-936.
101. Pec J., Palencarova E., Malisova S., Dobrota D., Hajtman A., Pec M., et al. Urticaria pigmentosa in identical male twins. Acta Derm Venereol 1995, 75:244.
102. Trevisan G., Pauluzzi P., Gatti A., Semeraro A. Familial mastocytosis associated with neurosensory deafness. J Eur Acad Dermatol Venereol 2000, 14:119-122.
103. Ben-Amitai D., Metzker A., Cohen H.A. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J 2005, 7:320-322.
104. Yanagihori H., Oyama N., Nakamura K., Kaneko F. C-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005, 7:252-257.
105. de la Sotta P.D., Romero W.A., Kramer D., Cárdenas C., González S. Cutaneous mastocytosis in twins: multiple mastocytomas and urticaria pigmentosa in two pairs of monozygotic twins. Pediatr Dermatol 2011, 28:585-587.
106. Wang H.J., Lin Z.M., Zhang J., Yin J.H., Yang Y. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family. Clin Exp Dermatol 2014, 39:146-149.
107. Fett N.M., Teng J., Longley B.J. Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations. Am J Dermatopathol 2013, 35:113-116.
108. Sato-Matsumura K.C., Matsumura T., Koizumi H., Sato H., Nagashima K., Ohkawara A. Analysis of c-kit exon 11 and exon 17 of urticaria pigmentosa that occurred in monozygotic twin sisters. Br J Dermatol 1999, 140:1130-1132.
109. Itzykson R., Kosmider O., Cluzeau T., Mansat-De Mas V., Dreyfus F., Beyne-Rauzy O., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
110. Bejar R., Stevenson K., Stojanov P., Zaneveld J.E., Bar-Natan M., Caughey B., et al. Next generation sequencing of 213 MDS patient samples identifies mutation profiles associated with response to hypomethylating agents and overall survival [abstract]. Leukemia Res 2013, 37(Suppl 1):519-520.
111. Thol F., Koenecke C., Dobbernack V., Kade S., Huang L., Platzbecker U., et al. Splicing gene mutations in MDS and secondary AML: Clinical implications in the setting of allogeneic hematopoietic stem cell transplantation [abstract]. Leukemia Res 2013, 37(Suppl 1):118-119.
112. Issa J.P. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 2013, 121:3811-3817.
113. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
114. Abdel-Wahab O., Levine R.L. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013, 121:3563-3572.
115. Bonnal S., Vigevani L., Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012, 11:847-859.
116. Ward A.F., Braun B.S., Shannon K.M. Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012, 120:3397-3406.
117. Pignon J.M., Giraudier S., Duquesnoy P., Jouault H., Imbert M., Vainchenker W., et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997, 96:374-376.
118. Galderisi C.D., Corless C.L., Wolford J., Harrell T., Heinrich M.C., Press R.D. Simultaneous JAK2 V617F and KIT D816V mutations in systemic mastocytosis. Modern Pathology 2006, 19:225A-226A.
119. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209.
120. Thachil J., Hawkins S., Woodcock B. JAK2-positive myeloproliferative neoplasm co-existing with systemic mastocytosis. Br J Haematol 2011, 152:675.
121. Broesby-Olsen S., Kristensen T.K., Møller M.B., Bindslev-Jensen C., Vestergaard H. Mastocytosis Centre. Odense University Hospital (MastOUH). Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. J Allergy Clin Immunol 2012, 130:806-808.
122. Visconte V., Tabarroki A., Rogers H.J., Hasrouni E., Traina F., Makishima H., et al. SF3B1 mutations are infrequently found in non-Myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica 2013, 98:e105-e107.
123. Wilson T.M., Maric I., Simakova O., Bai Y., Chan E.C., Olivares N., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96:459-463.
124. Nedoszytko B., Niedoszytko M., Lange M., van Doormaal J., Gleń J., Zabłotna M., et al. Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy 2009, 64:287-294.
125. Daley T., Metcalfe D.D., Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 2001, 98:880-882.
126. Nedoszytko B., Niedoszytko M., Lange M., van Doormaal J., Glen J., Zabotna M., et al. Associations of TNF-alpha gene polymorphisms and mastocytosis. A study of the European Competence Network in Mastocytosis (ECNM) [abstract]. Allergy 2008, 63(Suppl 88):154.
127. Mayeur-Rousse C., Sorel N., Voldoire M., Canioni D., Brizard F., Randriamalala E., et al. Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene. Leuk Res 2012, 36:377-381.
128. Tefferi A., Lasho T.L., Brockman S.R., Elliott M.A., Dispenzieri A., Pardanani A. FIP1L1- PDGFRA and c-kit D816V mutation- based clonality studies in systemic mast cell disease associated with eosinophilia Haematologica 2004, 89:871-873.
129. Yamada Y., Cancelas J.A. FIP1L1/PDGFR alpha-associated systemic mastocytosis. Int Arch Allergy Immunol 2010, 152(Suppl 1):101-105.
130. Tefferi A., Levine R.L., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. Frequent TET2 mutations in systemic mastocytosis: clinical KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
131. Schroer B.C., Han Y.C., Hsieh F.H. Identification of TET2 mutations in subjects with systemic mastocytosis and hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 125:AB232.
132. Pullarkat V., Bedell V., Kim Y., Bhatia R., Nakamura R., Forman S., et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007, 31:261-265.
133. Pullarkat S.T., Pullarkat V., Lagoo A., Brynes R., Weiss L.M., Bedell V., et al. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Leuk Res 2013, 37:1572-1575.
134. Bonadonna P., Perbellini O., Passalacqua G., Caruso B., Colarossi S., Dal Fior D., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009, 123:680-686.
135. Wöhrl S., Moritz K.B., Bracher A., Fischer G., Stingl G., Loewe R. A c-kit mutation in exon 18 in familial mastocytosis. J Invest Dermatol 2013, 133:839-841.
136. Sotlar K., Fridrich C., Mall A., Jaussi R., Bültmann B., Valent P., et al. Detection of c- kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002, 26:979-984.
137. Ozer O., Zhao Y.D., Ostler K.R., Akin C., Anastasi J., Vardiman J.W., et al. The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells. Leuk Lymphoma 2008, 49:1567-1577.
138. Georgin-Lavialle S., Lhermitte L., Suarez F., Yang Y., Letard S., Hanssens K., et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-kit tyrosine kinase inhibitor. Eur J Haematol 2012, 89:47-52.
139. Joris M., Georgin-Lavialle S., Chandesris M.O., Lhermitte L., Claisse J.F., Canioni D., et al. Mast cell leukaemia: c-kit mutations are not always positive. Case Report Hematol 2012, 2012:517546.
140. Park S.H., Chi H.S., Cho Y.U., Jang S., Park C.J., Lee J.H. A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17. Int J Lab Hematol 2014, 36:e44-e46.
141. Hartmann K., Wardelmann E., Ma Y., Merkelbach-Bruse S., Preussenr L.M., Woolery C., et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005, 129:1042-1046.
142. Speight R.A., Nicolle A., Needham S.J., Verrill M.W., Bryon J., Panter S. Rare germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis. J Clin Oncol 2013, 31:e245-e247.
143. de Melo Campos P., Machado-Neto J.A., Duarte A.S.S., Scopim-Ribeiro R., de Carvalho Barra F.F., Vassallo J., et al. Familial mastocytosis: identification of KIT K509I mutation and its in vitro sensitivity to imatinib, dasatinib and PK412. Blood 2013, 122:5267.
144. Zhang L.Y., Smith M.L., Schultheis B., Fitzgibbon J., Lister T.A., Melo J.V., et al. A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leukemia Res 2006, 30:373-378.
145. Akin C., Fumo G., Yavuz A.S., Lipsky P.E., Neckers L., Metcalfe D.D. A novel form of mastocytosis associated with a transmembrane c- Kit mutation and response to imatinib. Blood 2004, 103:3222-3225.
146. Escribano L., Nunez-Lopez R., Jara M., Garcia-Montero A., Prados A., Teodosio C., et al. Indolent systemic mastocytosis with germline D816V somatic c-kit mutation evolving to an acute myeloid leukemia. J Allery Clin Immunol 2006, 117(Suppl.):S125.
147. Chan E.C., Bai Y., Kirshenbaum A.S., Fischer E.R., Simakova O., Bandara G., et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol 2014, 134:178-187.
148. Spector M.S., Iossifov I., Kritharis A., He C., Kolitz J.E., Lowe S.W., et al. Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A. Leukemia 2012, 26:1422-1425.
149. Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K., Nakamura H., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998, 19:323-324.